Review



fsl1 tlr2 tlr6  (InvivoGen)


Bioz Verified Symbol InvivoGen is a verified supplier
Bioz Manufacturer Symbol InvivoGen manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    InvivoGen fsl1 tlr2 tlr6
    (A) Bmp6 mRNA expression in primary LSECs treated with 5 ng/mL LPS or 2.5 μM heme for 6 h in the presence or absence of hepatocyte-conditioned medium. (B) Bmp6 mRNA expression in primary LSECs treated with various TLR ligands: Pam3CSK4 <t>(TLR1/2),</t> PGN <t>(TLR2),</t> Poly I:C (TLR3), LPS (TLR4), FLA-ST (TLR5), <t>FSL1</t> (TLR2/6), R848 (TLR7/8), and ODN (TLR9) or vehicle control (NT, non-treated) for 6 h. (C-D) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of LPS for 6 h or with 5 ng/mL LPS for 2, 4, and 6 h. (E) Bmp6 mRNA expression in LSECs treated with 2.5 μM heme or protoporphyrin IX (PPIX) for 6 h. (F-G) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of heme for 6 h or treated with 2.5 μM heme for 2, 4, or 6 h. (H) Bmp6 mRNA expression in primary LSECs pre-treated with TAK242 (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS or 2.5 μM heme treatment for 6 h. (I) Transcription factor activity analysis by RNA-seq of LSECs treated with heme with respect to untreated controls (contrast-wise), in presence of hepatocyte-conditioned medium. (J) Bmp6 mRNA expression in primary LSECs pre-treated with CHX (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS treatment for 6 h. Cell culture experiments, except those in panel A, were always conducted in the presence of hepatocyte-conditioned medium. Gene expression levels were assessed by RT-qPCR, normalized to the housekeeping gene Rpl19 , and expressed as fold change relative to vehicle-treated controls. The dashed line (ut) represents the mRNA expression of LSECs treated with the conditions shown, in the absence of LPS or heme. Data are obtained from three or four independent experiments and displayed as mean ± SD. Statistical significance: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA or Student’s t-test. CM, conditioned medium; PPIX, protoporphyrin IX; CHX, cycloheximide.
    Fsl1 Tlr2 Tlr6, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 621 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fsl1+tlr2+tlr6/FSL-1/bio_rxiv__64898__2026__05__07__723498-68-16-34
    Average 97 stars, based on 621 article reviews
    fsl1 tlr2 tlr6 - by Bioz Stars, 2026-10
    97/100 stars

    Images

    1) Product Images from "Liver sinusoidal endothelial cells integrate metabolic and immune signals for MAPK-dependent BMP6 regulation and hepcidin induction"

    Article Title: Liver sinusoidal endothelial cells integrate metabolic and immune signals for MAPK-dependent BMP6 regulation and hepcidin induction

    Journal: bioRxiv

    doi: 10.64898/2026.05.07.723498

    (A) Bmp6 mRNA expression in primary LSECs treated with 5 ng/mL LPS or 2.5 μM heme for 6 h in the presence or absence of hepatocyte-conditioned medium. (B) Bmp6 mRNA expression in primary LSECs treated with various TLR ligands: Pam3CSK4 (TLR1/2), PGN (TLR2), Poly I:C (TLR3), LPS (TLR4), FLA-ST (TLR5), FSL1 (TLR2/6), R848 (TLR7/8), and ODN (TLR9) or vehicle control (NT, non-treated) for 6 h. (C-D) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of LPS for 6 h or with 5 ng/mL LPS for 2, 4, and 6 h. (E) Bmp6 mRNA expression in LSECs treated with 2.5 μM heme or protoporphyrin IX (PPIX) for 6 h. (F-G) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of heme for 6 h or treated with 2.5 μM heme for 2, 4, or 6 h. (H) Bmp6 mRNA expression in primary LSECs pre-treated with TAK242 (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS or 2.5 μM heme treatment for 6 h. (I) Transcription factor activity analysis by RNA-seq of LSECs treated with heme with respect to untreated controls (contrast-wise), in presence of hepatocyte-conditioned medium. (J) Bmp6 mRNA expression in primary LSECs pre-treated with CHX (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS treatment for 6 h. Cell culture experiments, except those in panel A, were always conducted in the presence of hepatocyte-conditioned medium. Gene expression levels were assessed by RT-qPCR, normalized to the housekeeping gene Rpl19 , and expressed as fold change relative to vehicle-treated controls. The dashed line (ut) represents the mRNA expression of LSECs treated with the conditions shown, in the absence of LPS or heme. Data are obtained from three or four independent experiments and displayed as mean ± SD. Statistical significance: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA or Student’s t-test. CM, conditioned medium; PPIX, protoporphyrin IX; CHX, cycloheximide.
    Figure Legend Snippet: (A) Bmp6 mRNA expression in primary LSECs treated with 5 ng/mL LPS or 2.5 μM heme for 6 h in the presence or absence of hepatocyte-conditioned medium. (B) Bmp6 mRNA expression in primary LSECs treated with various TLR ligands: Pam3CSK4 (TLR1/2), PGN (TLR2), Poly I:C (TLR3), LPS (TLR4), FLA-ST (TLR5), FSL1 (TLR2/6), R848 (TLR7/8), and ODN (TLR9) or vehicle control (NT, non-treated) for 6 h. (C-D) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of LPS for 6 h or with 5 ng/mL LPS for 2, 4, and 6 h. (E) Bmp6 mRNA expression in LSECs treated with 2.5 μM heme or protoporphyrin IX (PPIX) for 6 h. (F-G) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of heme for 6 h or treated with 2.5 μM heme for 2, 4, or 6 h. (H) Bmp6 mRNA expression in primary LSECs pre-treated with TAK242 (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS or 2.5 μM heme treatment for 6 h. (I) Transcription factor activity analysis by RNA-seq of LSECs treated with heme with respect to untreated controls (contrast-wise), in presence of hepatocyte-conditioned medium. (J) Bmp6 mRNA expression in primary LSECs pre-treated with CHX (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS treatment for 6 h. Cell culture experiments, except those in panel A, were always conducted in the presence of hepatocyte-conditioned medium. Gene expression levels were assessed by RT-qPCR, normalized to the housekeeping gene Rpl19 , and expressed as fold change relative to vehicle-treated controls. The dashed line (ut) represents the mRNA expression of LSECs treated with the conditions shown, in the absence of LPS or heme. Data are obtained from three or four independent experiments and displayed as mean ± SD. Statistical significance: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA or Student’s t-test. CM, conditioned medium; PPIX, protoporphyrin IX; CHX, cycloheximide.

    Techniques Used: Expressing, Control, Activity Assay, RNA Sequencing, Cell Culture, Gene Expression, Quantitative RT-PCR

    Related Articles

    Expressing:

    Article Title: Liver sinusoidal endothelial cells integrate metabolic and immune signals for MAPK-dependent BMP6 regulation and hepcidin induction
    Article Snippet: Lipopolysaccharide (LPS) (#2630), myoglobin (#M1882), N-acetyl-L-cysteine (NAC) (#A7250), H 2 O 2 (#1.07209) and cycloheximide (CHX) (#01810) were purchased from Sigma-Aldrich and diluted in phosphate buffered solution (PBS) (LPS, myoglobin, NAC and H 2 O 2 ) or DMSO (CHX).Lipopolysaccharide (LPS) (#2630), myoglobin (#M1882), N-acetyl-L-cysteine (NAC) (#A7250), H 2 O 2 (#1.07209) and cycloheximide (CHX) (#01810) were purchased from Sigma-Aldrich and diluted in phosphate buffered solution (PBS) (LPS, myoglobin, NAC and H 2 O 2 ) or DMSO (CHX).. The TLR ligands Pam3CSK4 (TLR2:1) (#tlrl-pms), PGN-SA (TLR2) (#tlrl-pgns2), Poly I:C (TLR3) (#tlrl-picw), FLA-ST (TLR5) (#tlrl-stfla), FSL1 (TLR2:TLR6) (tlrl-fsl), R848 (TLR7:8) (#tlrl-r848-1), ODN (TLR9) (#tlrl-1826) and the MAPK inhibitor SP600125 (#tlrl-sp60) were purchased form Invivogen and diluted in PBS (TLR ligands) or DMSO (SP600125).. Ferric nitrilotriacetate (FeNTA) was prepared dissolving iron (III) chloride hexahydrate (Sigma-Aldrich #31232) and nitrilotriacetic acid disodium salt (NTA) (Sigma-Aldrich #N0128) in PBS.Ferric nitrilotriacetate (FeNTA) was prepared dissolving iron (III) chloride hexahydrate (Sigma-Aldrich #31232) and nitrilotriacetic acid disodium salt (NTA) (Sigma-Aldrich #N0128) in PBS.

    Control:

    Article Title: Liver sinusoidal endothelial cells integrate metabolic and immune signals for MAPK-dependent BMP6 regulation and hepcidin induction
    Article Snippet: Lipopolysaccharide (LPS) (#2630), myoglobin (#M1882), N-acetyl-L-cysteine (NAC) (#A7250), H 2 O 2 (#1.07209) and cycloheximide (CHX) (#01810) were purchased from Sigma-Aldrich and diluted in phosphate buffered solution (PBS) (LPS, myoglobin, NAC and H 2 O 2 ) or DMSO (CHX).Lipopolysaccharide (LPS) (#2630), myoglobin (#M1882), N-acetyl-L-cysteine (NAC) (#A7250), H 2 O 2 (#1.07209) and cycloheximide (CHX) (#01810) were purchased from Sigma-Aldrich and diluted in phosphate buffered solution (PBS) (LPS, myoglobin, NAC and H 2 O 2 ) or DMSO (CHX).. The TLR ligands Pam3CSK4 (TLR2:1) (#tlrl-pms), PGN-SA (TLR2) (#tlrl-pgns2), Poly I:C (TLR3) (#tlrl-picw), FLA-ST (TLR5) (#tlrl-stfla), FSL1 (TLR2:TLR6) (tlrl-fsl), R848 (TLR7:8) (#tlrl-r848-1), ODN (TLR9) (#tlrl-1826) and the MAPK inhibitor SP600125 (#tlrl-sp60) were purchased form Invivogen and diluted in PBS (TLR ligands) or DMSO (SP600125).. Ferric nitrilotriacetate (FeNTA) was prepared dissolving iron (III) chloride hexahydrate (Sigma-Aldrich #31232) and nitrilotriacetic acid disodium salt (NTA) (Sigma-Aldrich #N0128) in PBS.Ferric nitrilotriacetate (FeNTA) was prepared dissolving iron (III) chloride hexahydrate (Sigma-Aldrich #31232) and nitrilotriacetic acid disodium salt (NTA) (Sigma-Aldrich #N0128) in PBS.

    Activity Assay:

    Article Title: Liver sinusoidal endothelial cells integrate metabolic and immune signals for MAPK-dependent BMP6 regulation and hepcidin induction
    Article Snippet: Lipopolysaccharide (LPS) (#2630), myoglobin (#M1882), N-acetyl-L-cysteine (NAC) (#A7250), H 2 O 2 (#1.07209) and cycloheximide (CHX) (#01810) were purchased from Sigma-Aldrich and diluted in phosphate buffered solution (PBS) (LPS, myoglobin, NAC and H 2 O 2 ) or DMSO (CHX).Lipopolysaccharide (LPS) (#2630), myoglobin (#M1882), N-acetyl-L-cysteine (NAC) (#A7250), H 2 O 2 (#1.07209) and cycloheximide (CHX) (#01810) were purchased from Sigma-Aldrich and diluted in phosphate buffered solution (PBS) (LPS, myoglobin, NAC and H 2 O 2 ) or DMSO (CHX).. The TLR ligands Pam3CSK4 (TLR2:1) (#tlrl-pms), PGN-SA (TLR2) (#tlrl-pgns2), Poly I:C (TLR3) (#tlrl-picw), FLA-ST (TLR5) (#tlrl-stfla), FSL1 (TLR2:TLR6) (tlrl-fsl), R848 (TLR7:8) (#tlrl-r848-1), ODN (TLR9) (#tlrl-1826) and the MAPK inhibitor SP600125 (#tlrl-sp60) were purchased form Invivogen and diluted in PBS (TLR ligands) or DMSO (SP600125).. Ferric nitrilotriacetate (FeNTA) was prepared dissolving iron (III) chloride hexahydrate (Sigma-Aldrich #31232) and nitrilotriacetic acid disodium salt (NTA) (Sigma-Aldrich #N0128) in PBS.Ferric nitrilotriacetate (FeNTA) was prepared dissolving iron (III) chloride hexahydrate (Sigma-Aldrich #31232) and nitrilotriacetic acid disodium salt (NTA) (Sigma-Aldrich #N0128) in PBS.

    RNA Sequencing:

    Article Title: Liver sinusoidal endothelial cells integrate metabolic and immune signals for MAPK-dependent BMP6 regulation and hepcidin induction
    Article Snippet: Lipopolysaccharide (LPS) (#2630), myoglobin (#M1882), N-acetyl-L-cysteine (NAC) (#A7250), H 2 O 2 (#1.07209) and cycloheximide (CHX) (#01810) were purchased from Sigma-Aldrich and diluted in phosphate buffered solution (PBS) (LPS, myoglobin, NAC and H 2 O 2 ) or DMSO (CHX).Lipopolysaccharide (LPS) (#2630), myoglobin (#M1882), N-acetyl-L-cysteine (NAC) (#A7250), H 2 O 2 (#1.07209) and cycloheximide (CHX) (#01810) were purchased from Sigma-Aldrich and diluted in phosphate buffered solution (PBS) (LPS, myoglobin, NAC and H 2 O 2 ) or DMSO (CHX).. The TLR ligands Pam3CSK4 (TLR2:1) (#tlrl-pms), PGN-SA (TLR2) (#tlrl-pgns2), Poly I:C (TLR3) (#tlrl-picw), FLA-ST (TLR5) (#tlrl-stfla), FSL1 (TLR2:TLR6) (tlrl-fsl), R848 (TLR7:8) (#tlrl-r848-1), ODN (TLR9) (#tlrl-1826) and the MAPK inhibitor SP600125 (#tlrl-sp60) were purchased form Invivogen and diluted in PBS (TLR ligands) or DMSO (SP600125).. Ferric nitrilotriacetate (FeNTA) was prepared dissolving iron (III) chloride hexahydrate (Sigma-Aldrich #31232) and nitrilotriacetic acid disodium salt (NTA) (Sigma-Aldrich #N0128) in PBS.Ferric nitrilotriacetate (FeNTA) was prepared dissolving iron (III) chloride hexahydrate (Sigma-Aldrich #31232) and nitrilotriacetic acid disodium salt (NTA) (Sigma-Aldrich #N0128) in PBS.

    Cell Culture:

    Article Title: Liver sinusoidal endothelial cells integrate metabolic and immune signals for MAPK-dependent BMP6 regulation and hepcidin induction
    Article Snippet: Lipopolysaccharide (LPS) (#2630), myoglobin (#M1882), N-acetyl-L-cysteine (NAC) (#A7250), H 2 O 2 (#1.07209) and cycloheximide (CHX) (#01810) were purchased from Sigma-Aldrich and diluted in phosphate buffered solution (PBS) (LPS, myoglobin, NAC and H 2 O 2 ) or DMSO (CHX).Lipopolysaccharide (LPS) (#2630), myoglobin (#M1882), N-acetyl-L-cysteine (NAC) (#A7250), H 2 O 2 (#1.07209) and cycloheximide (CHX) (#01810) were purchased from Sigma-Aldrich and diluted in phosphate buffered solution (PBS) (LPS, myoglobin, NAC and H 2 O 2 ) or DMSO (CHX).. The TLR ligands Pam3CSK4 (TLR2:1) (#tlrl-pms), PGN-SA (TLR2) (#tlrl-pgns2), Poly I:C (TLR3) (#tlrl-picw), FLA-ST (TLR5) (#tlrl-stfla), FSL1 (TLR2:TLR6) (tlrl-fsl), R848 (TLR7:8) (#tlrl-r848-1), ODN (TLR9) (#tlrl-1826) and the MAPK inhibitor SP600125 (#tlrl-sp60) were purchased form Invivogen and diluted in PBS (TLR ligands) or DMSO (SP600125).. Ferric nitrilotriacetate (FeNTA) was prepared dissolving iron (III) chloride hexahydrate (Sigma-Aldrich #31232) and nitrilotriacetic acid disodium salt (NTA) (Sigma-Aldrich #N0128) in PBS.Ferric nitrilotriacetate (FeNTA) was prepared dissolving iron (III) chloride hexahydrate (Sigma-Aldrich #31232) and nitrilotriacetic acid disodium salt (NTA) (Sigma-Aldrich #N0128) in PBS.

    Gene Expression:

    Article Title: Liver sinusoidal endothelial cells integrate metabolic and immune signals for MAPK-dependent BMP6 regulation and hepcidin induction
    Article Snippet: Lipopolysaccharide (LPS) (#2630), myoglobin (#M1882), N-acetyl-L-cysteine (NAC) (#A7250), H 2 O 2 (#1.07209) and cycloheximide (CHX) (#01810) were purchased from Sigma-Aldrich and diluted in phosphate buffered solution (PBS) (LPS, myoglobin, NAC and H 2 O 2 ) or DMSO (CHX).Lipopolysaccharide (LPS) (#2630), myoglobin (#M1882), N-acetyl-L-cysteine (NAC) (#A7250), H 2 O 2 (#1.07209) and cycloheximide (CHX) (#01810) were purchased from Sigma-Aldrich and diluted in phosphate buffered solution (PBS) (LPS, myoglobin, NAC and H 2 O 2 ) or DMSO (CHX).. The TLR ligands Pam3CSK4 (TLR2:1) (#tlrl-pms), PGN-SA (TLR2) (#tlrl-pgns2), Poly I:C (TLR3) (#tlrl-picw), FLA-ST (TLR5) (#tlrl-stfla), FSL1 (TLR2:TLR6) (tlrl-fsl), R848 (TLR7:8) (#tlrl-r848-1), ODN (TLR9) (#tlrl-1826) and the MAPK inhibitor SP600125 (#tlrl-sp60) were purchased form Invivogen and diluted in PBS (TLR ligands) or DMSO (SP600125).. Ferric nitrilotriacetate (FeNTA) was prepared dissolving iron (III) chloride hexahydrate (Sigma-Aldrich #31232) and nitrilotriacetic acid disodium salt (NTA) (Sigma-Aldrich #N0128) in PBS.Ferric nitrilotriacetate (FeNTA) was prepared dissolving iron (III) chloride hexahydrate (Sigma-Aldrich #31232) and nitrilotriacetic acid disodium salt (NTA) (Sigma-Aldrich #N0128) in PBS.

    Quantitative RT-PCR:

    Article Title: Liver sinusoidal endothelial cells integrate metabolic and immune signals for MAPK-dependent BMP6 regulation and hepcidin induction
    Article Snippet: Lipopolysaccharide (LPS) (#2630), myoglobin (#M1882), N-acetyl-L-cysteine (NAC) (#A7250), H 2 O 2 (#1.07209) and cycloheximide (CHX) (#01810) were purchased from Sigma-Aldrich and diluted in phosphate buffered solution (PBS) (LPS, myoglobin, NAC and H 2 O 2 ) or DMSO (CHX).Lipopolysaccharide (LPS) (#2630), myoglobin (#M1882), N-acetyl-L-cysteine (NAC) (#A7250), H 2 O 2 (#1.07209) and cycloheximide (CHX) (#01810) were purchased from Sigma-Aldrich and diluted in phosphate buffered solution (PBS) (LPS, myoglobin, NAC and H 2 O 2 ) or DMSO (CHX).. The TLR ligands Pam3CSK4 (TLR2:1) (#tlrl-pms), PGN-SA (TLR2) (#tlrl-pgns2), Poly I:C (TLR3) (#tlrl-picw), FLA-ST (TLR5) (#tlrl-stfla), FSL1 (TLR2:TLR6) (tlrl-fsl), R848 (TLR7:8) (#tlrl-r848-1), ODN (TLR9) (#tlrl-1826) and the MAPK inhibitor SP600125 (#tlrl-sp60) were purchased form Invivogen and diluted in PBS (TLR ligands) or DMSO (SP600125).. Ferric nitrilotriacetate (FeNTA) was prepared dissolving iron (III) chloride hexahydrate (Sigma-Aldrich #31232) and nitrilotriacetic acid disodium salt (NTA) (Sigma-Aldrich #N0128) in PBS.Ferric nitrilotriacetate (FeNTA) was prepared dissolving iron (III) chloride hexahydrate (Sigma-Aldrich #31232) and nitrilotriacetic acid disodium salt (NTA) (Sigma-Aldrich #N0128) in PBS.



    Similar Products

    fsl1 tlr2 tlr6  (InvivoGen)
    97
    InvivoGen fsl1 tlr2 tlr6
    (A) Bmp6 mRNA expression in primary LSECs treated with 5 ng/mL LPS or 2.5 μM heme for 6 h in the presence or absence of hepatocyte-conditioned medium. (B) Bmp6 mRNA expression in primary LSECs treated with various TLR ligands: Pam3CSK4 <t>(TLR1/2),</t> PGN <t>(TLR2),</t> Poly I:C (TLR3), LPS (TLR4), FLA-ST (TLR5), <t>FSL1</t> (TLR2/6), R848 (TLR7/8), and ODN (TLR9) or vehicle control (NT, non-treated) for 6 h. (C-D) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of LPS for 6 h or with 5 ng/mL LPS for 2, 4, and 6 h. (E) Bmp6 mRNA expression in LSECs treated with 2.5 μM heme or protoporphyrin IX (PPIX) for 6 h. (F-G) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of heme for 6 h or treated with 2.5 μM heme for 2, 4, or 6 h. (H) Bmp6 mRNA expression in primary LSECs pre-treated with TAK242 (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS or 2.5 μM heme treatment for 6 h. (I) Transcription factor activity analysis by RNA-seq of LSECs treated with heme with respect to untreated controls (contrast-wise), in presence of hepatocyte-conditioned medium. (J) Bmp6 mRNA expression in primary LSECs pre-treated with CHX (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS treatment for 6 h. Cell culture experiments, except those in panel A, were always conducted in the presence of hepatocyte-conditioned medium. Gene expression levels were assessed by RT-qPCR, normalized to the housekeeping gene Rpl19 , and expressed as fold change relative to vehicle-treated controls. The dashed line (ut) represents the mRNA expression of LSECs treated with the conditions shown, in the absence of LPS or heme. Data are obtained from three or four independent experiments and displayed as mean ± SD. Statistical significance: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA or Student’s t-test. CM, conditioned medium; PPIX, protoporphyrin IX; CHX, cycloheximide.
    Fsl1 Tlr2 Tlr6, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fsl1+tlr2+tlr6/FSL-1/bio_rxiv__64898__2026__05__07__723498-68-16-34
    Average 97 stars, based on 1 article reviews
    fsl1 tlr2 tlr6 - by Bioz Stars, 2026-10
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) Bmp6 mRNA expression in primary LSECs treated with 5 ng/mL LPS or 2.5 μM heme for 6 h in the presence or absence of hepatocyte-conditioned medium. (B) Bmp6 mRNA expression in primary LSECs treated with various TLR ligands: Pam3CSK4 (TLR1/2), PGN (TLR2), Poly I:C (TLR3), LPS (TLR4), FLA-ST (TLR5), FSL1 (TLR2/6), R848 (TLR7/8), and ODN (TLR9) or vehicle control (NT, non-treated) for 6 h. (C-D) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of LPS for 6 h or with 5 ng/mL LPS for 2, 4, and 6 h. (E) Bmp6 mRNA expression in LSECs treated with 2.5 μM heme or protoporphyrin IX (PPIX) for 6 h. (F-G) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of heme for 6 h or treated with 2.5 μM heme for 2, 4, or 6 h. (H) Bmp6 mRNA expression in primary LSECs pre-treated with TAK242 (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS or 2.5 μM heme treatment for 6 h. (I) Transcription factor activity analysis by RNA-seq of LSECs treated with heme with respect to untreated controls (contrast-wise), in presence of hepatocyte-conditioned medium. (J) Bmp6 mRNA expression in primary LSECs pre-treated with CHX (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS treatment for 6 h. Cell culture experiments, except those in panel A, were always conducted in the presence of hepatocyte-conditioned medium. Gene expression levels were assessed by RT-qPCR, normalized to the housekeeping gene Rpl19 , and expressed as fold change relative to vehicle-treated controls. The dashed line (ut) represents the mRNA expression of LSECs treated with the conditions shown, in the absence of LPS or heme. Data are obtained from three or four independent experiments and displayed as mean ± SD. Statistical significance: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA or Student’s t-test. CM, conditioned medium; PPIX, protoporphyrin IX; CHX, cycloheximide.

    Journal: bioRxiv

    Article Title: Liver sinusoidal endothelial cells integrate metabolic and immune signals for MAPK-dependent BMP6 regulation and hepcidin induction

    doi: 10.64898/2026.05.07.723498

    Figure Lengend Snippet: (A) Bmp6 mRNA expression in primary LSECs treated with 5 ng/mL LPS or 2.5 μM heme for 6 h in the presence or absence of hepatocyte-conditioned medium. (B) Bmp6 mRNA expression in primary LSECs treated with various TLR ligands: Pam3CSK4 (TLR1/2), PGN (TLR2), Poly I:C (TLR3), LPS (TLR4), FLA-ST (TLR5), FSL1 (TLR2/6), R848 (TLR7/8), and ODN (TLR9) or vehicle control (NT, non-treated) for 6 h. (C-D) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of LPS for 6 h or with 5 ng/mL LPS for 2, 4, and 6 h. (E) Bmp6 mRNA expression in LSECs treated with 2.5 μM heme or protoporphyrin IX (PPIX) for 6 h. (F-G) Bmp6 mRNA expression in primary LSECs treated with increasing concentrations of heme for 6 h or treated with 2.5 μM heme for 2, 4, or 6 h. (H) Bmp6 mRNA expression in primary LSECs pre-treated with TAK242 (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS or 2.5 μM heme treatment for 6 h. (I) Transcription factor activity analysis by RNA-seq of LSECs treated with heme with respect to untreated controls (contrast-wise), in presence of hepatocyte-conditioned medium. (J) Bmp6 mRNA expression in primary LSECs pre-treated with CHX (5 μM) or DMSO for 1 h, followed by 5 ng/mL LPS treatment for 6 h. Cell culture experiments, except those in panel A, were always conducted in the presence of hepatocyte-conditioned medium. Gene expression levels were assessed by RT-qPCR, normalized to the housekeeping gene Rpl19 , and expressed as fold change relative to vehicle-treated controls. The dashed line (ut) represents the mRNA expression of LSECs treated with the conditions shown, in the absence of LPS or heme. Data are obtained from three or four independent experiments and displayed as mean ± SD. Statistical significance: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA or Student’s t-test. CM, conditioned medium; PPIX, protoporphyrin IX; CHX, cycloheximide.

    Article Snippet: The TLR ligands Pam3CSK4 (TLR2:1) (#tlrl-pms), PGN-SA (TLR2) (#tlrl-pgns2), Poly I:C (TLR3) (#tlrl-picw), FLA-ST (TLR5) (#tlrl-stfla), FSL1 (TLR2:TLR6) (tlrl-fsl), R848 (TLR7:8) (#tlrl-r848-1), ODN (TLR9) (#tlrl-1826) and the MAPK inhibitor SP600125 (#tlrl-sp60) were purchased form Invivogen and diluted in PBS (TLR ligands) or DMSO (SP600125).

    Techniques: Expressing, Control, Activity Assay, RNA Sequencing, Cell Culture, Gene Expression, Quantitative RT-PCR